By Fineline Cube CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the New Drug Application (NDA) for its bispecific antibody anbenitamab (KN026) in combination with its independently developed docetaxel for injection (albumin‑bound) (HB1801) has been accepted by China’s National Medical Products Administration (NMPA) for the first‑line treatment of advanced breast cancer.
Anbenitamab is co‑developed by CSPC’s subsidiary JMT‑Bio and Alphamab Oncology (9966.HK), underscoring a multi‑party oncology pipeline alliance.
NDA Summary
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Status | NDA accepted |
| Combination | Anbenitamab (KN026) + HB1801 (albumin‑bound docetaxel) |
| Indication | First‑line treatment of advanced breast cancer |
| Sponsor | CSPC Pharmaceutical Group (HKG: 1093) |
| Co‑Development | JMT‑Bio (CSPC subsidiary) × Alphamab Oncology (9966.HK) |
| Announcement Date | 19 Aug 2026 |
Drug Profile – Anbenitamab (KN026)
- Class: HER2‑targeted bispecific antibody
- Mechanism: Simultaneously binds two non‑overlapping epitopes of HER2, blocking HER2 signaling, enhancing HER2 internalization, and downregulating HER2 expression
- Effector Function: Retains antibody‑dependent cellular cytotoxicity (ADCC) effects
- Prior Approval: In May 2026, anbenitamab was approved for marketing in combination with chemotherapy for adult patients with locally advanced or metastatic HER2‑positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who had received at least one prior trastuzumab‑containing regimen
Drug Profile – HB1801
- Class: Novel albumin‑bound docetaxel formulation
- Design: Encapsulates docetaxel in human serum albumin
- Advantage: Offers significant advantages over conventional docetaxel injections, including improved formulation characteristics typically associated with albumin‑bound delivery
- Ownership: Independently developed by CSPC Pharmaceutical Group
Regulatory Momentum – Dual NDA Acceptances
| Filing | Combination | Setting | Status |
|---|---|---|---|
| Prior Filing | Anbenitamab + HB1801 | Neoadjuvant therapy for HER2‑positive early or locally advanced breast cancer | NDA accepted by NMPA |
| New Filing | Anbenitamab + HB1801 | First‑line advanced breast cancer | NDA accepted by NMPA |
The back‑to‑back NDA acceptances position the anbenitamab + HB1801 regimen across both early‑line neoadjuvant and first‑line advanced settings in HER2‑positive breast cancer.
Market Impact & Outlook
- Expanding HER2 Franchise: Anbenitamab’s May 2026 gastric/GEJ approval plus two breast cancer NDAs give CSPC a fast‑growing, multi‑indication HER2 asset competing in one of oncology’s most contested targets.
- Differentiated Backbone: Pairing a bispecific antibody with an albumin‑bound docetaxel (HB1801) offers a proprietary combination that rivals cannot easily replicate, strengthening CSPC’s negotiating and pricing position in China.
- Partnership Leverage: The JMT‑Bio × Alphamab Oncology co‑development model distributes R&D risk while consolidating commercial upside within CSPC’s established oncology salesforce.
- Watch Items: NMPA review timeline for the first‑line breast cancer indication, potential additional combination filings, and competitive pressure from other HER2‑targeted agents entering the Chinese market.
Forward-Looking Statements
This brief contains forward‑looking statements regarding regulatory review timelines, clinical outcomes, and commercial expectations for anbenitamab (KN026) and HB1801. Actual results may differ due to risks including NMPA review decisions, competitive dynamics, and market adoption in China.-Fineline Info & Tech